Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
---|---|
Information provided by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
ClinicalTrials.gov Identifier: | NCT00830037 |
The long-term goal is to assess the fall in kidney function measured by glomerular filtration rate (GFR) when patients with chronic kidney disease (CKD) are exposed to intravenous iron (IVIR). We hypothesize that in subjects with mild to moderate CKD, infusion of intravenous iron (IVIR), will generate oxidative stress and cause an inflammatory response that will be associated with a more rapid decline in glomerular filtration rate (GFR) compared to oral iron.
Condition | Intervention | Phase |
---|---|---|
Chronic Kidney Disease Iron-Deficiency Anemia |
Drug: IV Iron Drug: Ferrous Sulfate |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Pathobiology of Kidney Disease: Role of Iron |
Estimated Enrollment: | 200 |
Study Start Date: | August 2008 |
Estimated Study Completion Date: | August 2013 |
Estimated Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
IV Iron: Experimental |
Drug: IV Iron
IV iron sucrose 200 mg over 2 hours baseline visit, week 2, week 4, week 6 and week 8 for a total of 1000mg total dose. Further cycles of iv iron may be used based on periodic monitoring of iron stores.
|
Oral Iron: Active Comparator |
Drug: Ferrous Sulfate
Oral ferrous gluconate 325mg three times daily over 8 weeks. Further cycles of oral iron may be used based on periodic monitoring of iron stores.
|
Intravenous iron is commonly utilized and is likely a mechanism of renal injury in patients with CKD. This proposal will provide translational data on the role of intravenous iron to progression of kidney disease in patients with CKD. Comparison of IV iron with oral iron will allow testing the hypothesis that IVIR will generate an inflammatory response and albuminuria in the short-term, that will directly lead to a greater rate of fall in GFR, in the long-term, compared to oral iron. We hypothesize that after administration of one gram of IV iron over a course of 8 weeks, renal injury as documented by albuminuria (and fall in GFR) will be increased with IV iron sucrose therapy compared to those randomized to oral iron therapy. A randomized, parallel group, controlled trial will be performed. GFR will be measures every 6 months for two years in 200 participants by iothalamate clearances.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jennifer E Bills, BS | 317-988-4692 | jebills@iupui.edu |
Contact: Robert P Light | lightr@iupui.edu |
United States, Indiana | |
VA Medical Center | Recruiting |
Indianapolis, Indiana, United States, 46202 | |
Contact: Jenniger E Bills, BS 317-988-4692 jebills@iupui.edu | |
Contact: Robert Light lightr@iupui.edu |
Principal Investigator: | Rajiv Agarwal, MD, FASN, FAHA | Indiana University |
Responsible Party: | Indiana University ( Rajiv Agarwal, MD ) |
Study ID Numbers: | DK71633, 5U01DK071633-02 |
Study First Received: | January 26, 2009 |
Last Updated: | January 26, 2009 |
ClinicalTrials.gov Identifier: | NCT00830037 History of Changes |
Health Authority: | United States: Federal Government; United States: Food and Drug Administration |
anemia iron kidney disease progression glomerular filtration rate |
Renal Insufficiency Metabolic Diseases Hematologic Diseases Kidney Failure, Chronic Anemia Disease Progression Trace Elements Iron Metabolism Disorders Anemia, Iron-Deficiency |
Ferric oxide, saccharated Urologic Diseases Renal Insufficiency, Chronic Ferrous gluconate Micronutrients Kidney Diseases Iron Metabolic Disorder Kidney Failure |
Renal Insufficiency Metabolic Diseases Hematologic Diseases Growth Substances Physiological Effects of Drugs Kidney Failure, Chronic Anemia, Hypochromic Anemia Trace Elements |
Iron Metabolism Disorders Pharmacologic Actions Anemia, Iron-Deficiency Urologic Diseases Renal Insufficiency, Chronic Micronutrients Kidney Diseases Iron Kidney Failure |